Inotiv, Inc. ( (NOTV) ) has released its Q4 earnings. Here is a breakdown of the information Inotiv, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inotiv, Inc. is a prominent contract research organization that offers nonclinical and analytical drug discovery and development services, as well as research models and related products. The company operates primarily in the pharmaceutical and biotechnology sectors, focusing on enhancing drug development efficiency and reducing costs.
Inotiv reported its financial results for the fourth quarter and full fiscal year 2025, highlighting a revenue increase and a significant reduction in operating losses. The company achieved a 5.9% increase in fourth-quarter revenue to $138.1 million and a 4.5% increase in annual revenue to $513.0 million. Operating losses decreased by 48.5% in the fourth quarter and 64.2% for the full year, reflecting improved financial performance.
Key financial metrics showed a positive trend, with the Discovery & Safety Assessment (DSA) segment experiencing a 15.7% revenue increase in the fourth quarter. The Research Models & Services (RMS) segment also saw a modest revenue increase. The company’s adjusted EBITDA more than doubled in the fourth quarter compared to the previous year, indicating enhanced operational efficiency. Additionally, Inotiv engaged financial advisors to explore debt refinancing options and implemented site optimization plans, including property sales to repay loans.
Despite a cybersecurity incident in August 2025, Inotiv managed to restore its systems and is evaluating the incident’s impact. The company’s strategic focus on client satisfaction and operational improvements has contributed to its financial recovery and growth.
Looking ahead, Inotiv remains committed to executing its strategic plans to improve cash flow, margins, and client metrics. The management’s focus on operational efficiency and client satisfaction positions the company for continued progress in the drug discovery and development sector.